Crowdonomics
WatchlistPortfolio
All companies
AJNA BIOSCIENCES logo

AJNA BIOSCIENCES

Operating

AJNA BioSciences PBC

Biotech · Biotech · Littleton, CO

Visit website

Transforming the $678B pharmaceutical industry with plant medicine

Post-money valuation ⓘ
$126.1M
As of Oct 2025 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$12,079,359
Crowd $2.3M · Private $9.8M · 4 rounds since 2021
Latest share price
$4.83
Reg CF · Preferred Stock · Apr 2025 offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source
$415K
−$4.1M
2022
$4.6M
$9.4M
2023
$3.3M
−$2.4M
2024
$1.7M
−$3.8M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
FY2024 unaudited
FY2025
Income statement
Revenue
$415,364
$4,558,657
$3,267,479
$1,692,791
Cost of goods sold
$415,364
$4,558,657
$3,267,479
$1,692,791
Gross margin
0%
0%
0%
0%
Net income
-$4,066,700
$9,372,650
-$2,359,584
-$3,800,746
Taxes paid
$0
$30,000
$30,000
$0
Balance sheet
Cash
$532,128
$984,298
$1,927,679
$368,452
Accounts receivable
$415,364
$0
$0
$0
Total assets
$3,003,351
$13,306,444
$16,627,450
$13,800,386
Short-term debt
$1,176,130
$9,619,653
$512,725
$1,496,442
Long-term debt
$8,180,430
$715,011
$1,953,013
$385,819
Total liabilities
$9,356,560
$10,334,664
$2,465,738
$1,882,261
Other
Headcount
—
16
20
16

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$40.0M
pre-money
$125.0M
pre-money
Reg CF · Preferred · Jun 2024
Reg CF · Preferred · Apr 2025

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$4.83$2.415$1.3133
May 2024Apr 2025
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Reg CF · Preferred Stock · Apr 2025Closedvia StartEngine
Raised $1M / $1.5MInvestors 346Post-money $126.1M
Reg CF · Preferred Stock · Jun 2024Closedvia WeFunder
Raised $1.2M / $1.2MInvestors 552Post-money $41.2M
Rule 506(b) · Preferred Stock · May 2024Closed
Raised $2.9MInvestors 57
Rule 506(b) · Convertible Note · Sep 2021Closed
Raised $6.9MInvestors 27

Team

5 people
Joel Stanley
Chief Executive Officer

Leader in botanical drug innovation and CBD industry trailblazer. Scaled CBD category leader Charlotte's Web from 0 to IPO with $75M in annual revenue. Former Chairman at Charlotte’s Web.

Orrin Devinsky, MD
Chief Medical Advisor

Dr. Orrin Devinsky is a renowned neurologist and epilepsy specialist, serving as Director of the NYU Langone Comprehensive Epilepsy Center and Professor of Neurology, Neurosurgery, and Psychiatry at NYU Grossman School of Medicine. With decades of clinical and research experience, Dr. Devinsky has been a leading voice in advancing treatments for epilepsy and neurological disorders, including groundbreaking work on the use of cannabidiol (CBD) for seizure control. He has authored hundreds of scientific publications and is widely respected for his holistic approach to patient care and brain health.

Robert Judge
VP of Finance

In CFO roles for 30+ years in manufacturing, distribution, family office, and privately held businesses. Senior manager at KPMG working with public and private companies.

Scott Hansen, MBA
VP Operations + Quality

Development and QC Sandoz Pharmaceuticals, Director QC and R&D Charlotte's Web, VP QC and Regulatory Affairs Agricor/Botanacor

Jesse Stanley
Board Member

Original co-founder of Charlottes Web and co-founder of AJNA BioSciences. Worked in alternative medicine for last 15 years.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Compliant

Filed 2 of 2 annual reports (FY2024–FY2025)

552 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 11 filings on EDGAR
  • Form C-ARMay 13, 20260001900590-26-000003
    EDGAR
  • Form C-UNov 13, 20250001900590-25-000002
    EDGAR
  • Form C/ASep 10, 20250001665160-25-001419
    EDGAR
  • Form C/AJul 22, 20250001665160-25-001312
    EDGAR
  • Form C/AJul 8, 20250001665160-25-001274
    EDGAR
  • Form CApr 29, 20250001665160-25-000792
    EDGAR
  • Form C-ARApr 16, 20250001670254-25-000367
    EDGAR
  • Form C-UApr 2, 20250001670254-25-000282
    EDGAR
Source: ManualCIK 0001900590DEShare price $4.83

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.